Form 4: Vera Therapeutics Officer Sells Shares After Option Exercise

Vera Therapeutics' Chief Regulatory Officer, William D. Turner, exercised stock options and subsequently sold a portion of his Class A Common Stock.

Summary

• William D. Turner, Chief Regulatory Officer of Vera Therapeutics, Inc. (VERA), reported transactions on December 15, 2025.
• Turner exercised options to acquire 10,000 shares of Class A Common Stock at an exercise price of $15.53 per share.
• Concurrently, Turner sold 10,000 shares of Class A Common Stock at a weighted average price of $50.0767 per share, with prices ranging from $50.00 to $50.11.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.
• Following these transactions, Turner directly beneficially owns 22,500 shares of Class A Common Stock.
• Turner also holds 245,000 derivative securities in the form of stock options (right to buy) with an exercise price of $15.53, which vest over time.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling, even though it was pre-planned under a Rule 10b5-1 plan. While the exercise of options is a positive sign of value realization, the subsequent sale by a key officer can sometimes be interpreted as a lack of future confidence or simply a need for personal liquidity, which the market may view with caution.

Positives

• The exercise of stock options at $15.53 and subsequent sale at an average of $50.0767 indicates a significant profit for the reporting person, reflecting a substantial increase in the stock's value since the options were granted.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which demonstrates a commitment to compliance and mitigates concerns about opportunistic insider trading.

Negatives

• The sale of 10,000 shares by a Chief Regulatory Officer, even if pre-planned, could be perceived by some investors as a signal of reduced confidence or a desire for personal liquidity, potentially leading to negative sentiment.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends. Such transactions are common for executives managing their equity compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, potentially influencing their perception of the company's near-term prospects or the officer's confidence. However, the 10b5-1 plan mitigates some of this concern.
• Employees: No direct impact mentioned, but general market sentiment can affect employee morale and stock-based compensation value.

Key Dates

Keywords

Vera Therapeutics, VERA, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Chief Regulatory Officer